CClinicalTrials.gg
Sign In
CompletedNCT02773355Updated Apr 13, 2026

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

An observational study in Obesity, sponsored by Novo Nordisk A/S. Completed at 14 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Novo Nordisk A/S · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
27
Ages
18 Years and older
Sex
All
01

Study summary

This trial is conducted in North America. The aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to Saxenda® in Mexican patients.

02

Conditions studied

  • Obesity

Browse trials for

03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's enrollment of 27 is below the median of 135 across 1,283 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 102 are open to participants now.

Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The medical condition investigated in this study is obesity and overweight with one or more weight related comorbidities. The study will aim at observing all patients exposed to Saxenda® during treatment by the 20 participating physicians in Mexico.

Inclusion criteria

  • Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
  • The decision to initiate the treatment with commercially available Saxenda® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study
  • Obese patients (BMI equal to or above 30 kg/m\^2) or overweight patients (BMI Equal to or above 27 kg/m\^2) with at least one weight related comorbidity according to Saxenda® label text in Mexico
  • Age equal or above 18 years at the time of signing informed consent

Exclusion criteria

Exclusion Criteria:

  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  • Hypersensitivity to Saxenda® or to any of its excipients
  • Females of child-bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)
  • Diagnosis of type 1 diabetes
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
27 participants (actual)
Patient registry
No

Groups and cohorts

  • Saxenda®

    Drug: liraglutide 3.0 mg

Interventions

  • Drugliraglutide 3.0 mg

    Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.

06

What researchers measure

Primary outcomes

  1. Frequency of pancreatitis

    Time frame: Year 0-3

Secondary outcomes

  1. Adverse drug reactions (ADR)

    Time frame: Year 0-3

07

Study locations

14 sites
  • Especialidades Médicas del Bosque
    Guadalajara, Jalisco 44520, Mexico
  • Investigación Clínica Especializada, S.C.
    Guadalajara, Jalisco 44600, Mexico
  • Centro de Investigacion Clinica Endocrinologica de Jalisco
    Guadalajara, Jalisco 44670, Mexico
  • Unidad Médica Dentistas
    Guadalajara, Jalisco 44679, Mexico
  • Hospital Bite Medica
    Mexico City, México, D.F. 01330, Mexico
  • Hospital San Angel Inn
    Mexico City, México, D.F. 03339, Mexico
  • Hospital HMG Coyoacan
    Mexico City, México, D.F. 04380, Mexico
  • Hospital San Angel Inn_Mexico City
    Mexico City, México, D.F. 06700, Mexico
  • Torre Médica Dalinde
    Mexico City, México, D.F. 06760, Mexico
  • Zrii de México Ejecutivo Independiente
    Monterrey, Nuevo León 66220, Mexico
  • Hospital CIMA Hermosillo
    Hermosillo, Sonora 83270, Mexico
  • Hospital Angeles de las Lomas
    México, State of Mexico 52763, Mexico
  • Medica Sur
    Mexico City, 14050, Mexico
  • Hospital Angeles de Puebla
    Puebla City, 72190, Mexico
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02773355
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 16, 2016
Start date
May 16, 2016
Primary completion
Nov 30, 2021
Completion
Feb 28, 2022
Last update
Apr 13, 2026

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Obesity→

Other studies from this sponsor

Novo Nordisk A/S

Start the discussion